| Business Summary | | Aethlon
Medical,
Inc.
is
a
developer
and
marketer
of
extracorporeal
medical
device
technologies.
The
Company
has
applied
its
proprietary
platform
technology,
known
as
the
Hemopurifier,
to
develop
an
extracorporeal
therapeutic
treatment
for
HIV-AIDS.
Pre-clinical
trials
have
documented
the
rapid
removal
of
up
to
70%
of
the
HIV
virus
during
one
60-minute
application.
The
Company
is
in
the
initial
stages
of
its
operations,
and
has
not
yet
engaged
in
significant
commercial
activities.
During
the
fiscal
year
2001,
the
Company
plans
to
continue
its
research
and
development
activities
relating
to
the
Hemopurifier,
and
commence
clinical
trials
for
the
device
to
remove
iron
from
the
blood. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Aethlon
Medical,
Inc.
develops
and
markets
extra-corporeal
medical
device
technologies
by
using
a
proprietary
platform
technology
to
develop
disposable
products
that
remove
targeted
toxins
from
the
blood.
For
the
three
months
ended
6/30/01,
the
Company
reported
no
revenue.
Net
loss
rose
5%
to
$660
thousand.
Results
reflect
an
increase
in
professional
fees,
higher
other
amortization
expenses
and
a
rise
in
other
expenses. | More
from
Market Guide: Significant
Developments |
| | | Franklyn
Barry
Jr.,
Pres./CEO James
Joyce,
Chmn./
Secy. John
Murray,
VP-Fin./CFO Richard
Tullis
Ph.D.,
VP. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|